Research ExplorerPublicationsNilotinib and imatinib are comparably effective in reducing ...

Nilotinib and imatinib are comparably effective in reducing growth of human eosinophil leukemia cells in a newly established xenograft model.

Standard

Nilotinib and imatinib are comparably effective in reducing growth of human eosinophil leukemia cells in a newly established xenograft model. / Wicklein, Daniel; Ramos Leal, Nuno; Salamon, Johannes Martin; Thamer, Mohammed; Herrmann, Harald; Valent, Peter; Schumacher, Udo; Ullrich, Sebastian.

In: PLOS ONE, Vol. 7, No. 2, 2, 2012, p. 30567.

Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

Harvard

Wicklein, D, Ramos Leal, N, Salamon, JM, Thamer, M, Herrmann, H, Valent, P, Schumacher, U & Ullrich, S 2012, 'Nilotinib and imatinib are comparably effective in reducing growth of human eosinophil leukemia cells in a newly established xenograft model.', PLOS ONE, vol. 7, no. 2, 2, pp. 30567. https://doi.org/10.1371/journal.pone.0030567

APA

Wicklein, D., Ramos Leal, N., Salamon, J. M., Thamer, M., Herrmann, H., Valent, P., Schumacher, U., & Ullrich, S. (2012). Nilotinib and imatinib are comparably effective in reducing growth of human eosinophil leukemia cells in a newly established xenograft model. PLOS ONE, 7(2), 30567. [2]. https://doi.org/10.1371/journal.pone.0030567

Vancouver

Wicklein D, Ramos Leal N, Salamon JM, Thamer M, Herrmann H, Valent P et al. Nilotinib and imatinib are comparably effective in reducing growth of human eosinophil leukemia cells in a newly established xenograft model. PLOS ONE. 2012;7(2):30567. 2. https://doi.org/10.1371/journal.pone.0030567

Bibtex

@article{54a84a0de4614e828ef526a205ea99e1,
title = "Nilotinib and imatinib are comparably effective in reducing growth of human eosinophil leukemia cells in a newly established xenograft model.",
abstract = "We developed a xenograft model of human Chronic Eosinophilic Leukemia (CEL) to study disease progression and remission-induction under therapy with tyrosine kinase inhibitors using imatinib and nilotinib as examples. The FIP1L1/PDGFRA+ human CEL cell lineEOL-1 was injected intravenously into scid mice, and MR imaging and FACS analysis of mouse blood samples were performed to monitor disease development and the effects of imatinib and nilotinib. Organ infiltration was analyzed in detail by immunohistochemistry after sacrifice. All animals developed CEL and within one week of therapy, complete remissions were seen with both imatinib and nilotinib, resulting in reduced total tumor volumes by MR-imaging and almost complete disappearance of EOL-1 cells in the peripheral blood and in tissues. The new model system is feasible for the evaluation of new tyrosine kinase inhibitors and our data suggest that nilotinib may be a valuable additional targeted drug active in patients with FIP1L1/PDGFRA+ CEL.",
author = "Daniel Wicklein and {Ramos Leal}, Nuno and Salamon, {Johannes Martin} and Mohammed Thamer and Harald Herrmann and Peter Valent and Udo Schumacher and Sebastian Ullrich",
year = "2012",
doi = "10.1371/journal.pone.0030567",
language = "English",
volume = "7",
pages = "30567",
journal = "PLOS ONE",
issn = "1932-6203",
publisher = "Public Library of Science",
number = "2",

}

RIS

TY - JOUR

T1 - Nilotinib and imatinib are comparably effective in reducing growth of human eosinophil leukemia cells in a newly established xenograft model.

AU - Wicklein, Daniel

AU - Ramos Leal, Nuno

AU - Salamon, Johannes Martin

AU - Thamer, Mohammed

AU - Herrmann, Harald

AU - Valent, Peter

AU - Schumacher, Udo

AU - Ullrich, Sebastian

PY - 2012

Y1 - 2012

N2 - We developed a xenograft model of human Chronic Eosinophilic Leukemia (CEL) to study disease progression and remission-induction under therapy with tyrosine kinase inhibitors using imatinib and nilotinib as examples. The FIP1L1/PDGFRA+ human CEL cell lineEOL-1 was injected intravenously into scid mice, and MR imaging and FACS analysis of mouse blood samples were performed to monitor disease development and the effects of imatinib and nilotinib. Organ infiltration was analyzed in detail by immunohistochemistry after sacrifice. All animals developed CEL and within one week of therapy, complete remissions were seen with both imatinib and nilotinib, resulting in reduced total tumor volumes by MR-imaging and almost complete disappearance of EOL-1 cells in the peripheral blood and in tissues. The new model system is feasible for the evaluation of new tyrosine kinase inhibitors and our data suggest that nilotinib may be a valuable additional targeted drug active in patients with FIP1L1/PDGFRA+ CEL.

AB - We developed a xenograft model of human Chronic Eosinophilic Leukemia (CEL) to study disease progression and remission-induction under therapy with tyrosine kinase inhibitors using imatinib and nilotinib as examples. The FIP1L1/PDGFRA+ human CEL cell lineEOL-1 was injected intravenously into scid mice, and MR imaging and FACS analysis of mouse blood samples were performed to monitor disease development and the effects of imatinib and nilotinib. Organ infiltration was analyzed in detail by immunohistochemistry after sacrifice. All animals developed CEL and within one week of therapy, complete remissions were seen with both imatinib and nilotinib, resulting in reduced total tumor volumes by MR-imaging and almost complete disappearance of EOL-1 cells in the peripheral blood and in tissues. The new model system is feasible for the evaluation of new tyrosine kinase inhibitors and our data suggest that nilotinib may be a valuable additional targeted drug active in patients with FIP1L1/PDGFRA+ CEL.

U2 - 10.1371/journal.pone.0030567

DO - 10.1371/journal.pone.0030567

M3 - SCORING: Journal article

VL - 7

SP - 30567

JO - PLOS ONE

JF - PLOS ONE

SN - 1932-6203

IS - 2

M1 - 2

ER -